Biodegradation of the Antiretroviral Tenofovir Disoproxil by a Cyanobacteria/Bacterial Culture

被引:1
|
作者
Silva, Sandra Regina [1 ]
Souza-Silva, Gabriel [1 ]
Moreira, Carolina Paula de Souza [2 ]
Vasconcelos, Olivia Maria de Sousa Ribeiro [2 ]
Silveira, Micheline Rosa [1 ]
Barbosa, Francisco Antonio Rodrigues [1 ]
Magalhaes, Sergia Maria Starling [1 ]
Mol, Marcos Paulo Gomes [2 ]
机构
[1] Univ Fed Minas Gerais, Fac Farm, BR-30510010 Belo Horizonte, Brazil
[2] Fundacao Ezequiel Dias, Dept Pesquisa & Desenvolvimento, BR-30510010 Belo Horizonte, Brazil
关键词
drug; <italic>Microcystis novacekii</italic>; <italic>Pseudomonas pseudoalcaligenes</italic>; by-products; tenofovir isoproxil monoester; WASTE-WATER; SURFACE-WATER; CYANOBACTERIUM; ALGAL; PHARMACEUTICALS; MICROALGAE; FUMARATE; ADAPTATION; STABILITY; RESIDUES;
D O I
10.3390/toxics12100729
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Tenofovir disoproxil fumarate (TDF) is an antiretroviral drug extensively used by people living with HIV. The TDF molecule is hydrolysed in vivo and liberates tenofovir, the active part of the molecule. Tenofovir is a very stable drug and the discharge of its residues into the environment can potentially lead to risk for aquatic species. This study evaluated the TDF biodegradation and removal by cultures of Microcystis novacekii with the bacteria Pseudomonas pseudoalcaligenes. Concentrations of TDF of 12.5, 25.0, and 50.0 mg/L were used in this study. The process occurred in two stages. In the first 72 h, TDF was de-esterified, forming the tenofovir monoester intermediate by abiotic and enzymatic processes associated in an extracellular medium. In a second step, the monoester was removed from the culture medium by intracellular processes. The tenofovir or other by-products of TDF were not observed in the test conditions. At the end of the experiment, 88.7 to 94.1% of TDF and its monoester derivative were removed from the culture medium over 16 days. This process showed higher efficiency of TDF removal at the concentration of 25 mg/L. Tenofovir isoproxil monoester has partial antiviral activity and has shown to be persistent, maintaining a residual concentration after 16 days in the culture medium, therefore indicating the need to continue research on methods for total removal of this product from the aquatic environment.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Experience with tenofovir disoproxil fumarate for antiretroviral therapy
    Stephan, Christoph
    EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (07) : 1197 - 1209
  • [2] Commentary: The Place of Tenofovir Disoproxil Fumarate in Pediatric Antiretroviral Therapy
    Havens, Peter L.
    Hazra, Rohan
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2015, 34 (04) : 406 - 408
  • [3] Thermal characterization and kinetic study of the antiretroviral tenofovir disoproxil fumarate
    Jéssica Priscila Avelino Silva
    Camila Bezerra Melo Figueirêdo
    Amanda Carla Quintas de Medeiros Vieira
    Magaly Andreza Marques de Lyra
    Larissa Araújo Rolim
    Pedro José Rolim-Neto
    Mônica Felts de La Roca Soares
    Miracy Muniz Albuquerque
    José Lamartine Soares-Sobrinho
    Journal of Thermal Analysis and Calorimetry, 2017, 130 : 1643 - 1651
  • [4] Thermal characterization and kinetic study of the antiretroviral tenofovir disoproxil fumarate
    Avelino Silva, Jessica Priscila
    Melo Figueiredo, Camila Bezerra
    Quintas de Medeiros Vieira, Amanda Carla
    Marques de Lyra, Magaly Andreza
    Rolim, Larissa Araujo
    Rolim-Neto, Pedro Jose
    de La Roca Soares, Monica Felts
    Albuquerque, Miracy Muniz
    Soares-Sobrinho, Jose Lamartine
    JOURNAL OF THERMAL ANALYSIS AND CALORIMETRY, 2017, 130 (03) : 1643 - 1651
  • [5] Divergent effects of the antiretroviral drugs, dolutegravir, tenofovir alafenamide, and tenofovir disoproxil fumarate, on human adipocyte function
    Quesada-Lopez, T.
    Cereijo, R.
    Blasco-Roset, A.
    Mestres-Arenas, A.
    Prieto, P.
    Domingo, J. C.
    Villarroya, F.
    Domingo, P.
    Giralt, M.
    BIOCHEMICAL PHARMACOLOGY, 2024, 220
  • [7] Tenofovir Disoproxil Fumarate
    Therese M. Chapman
    Jane K. McGavin
    Stuart Noble
    Drugs, 2003, 63 : 1597 - 1608
  • [8] Tenofovir disoproxil fumarate
    Grim, SA
    Romanelli, F
    ANNALS OF PHARMACOTHERAPY, 2003, 37 (06) : 849 - 859
  • [9] Tenofovir disoproxil fumarate
    Nestor, RJ
    ANNALS OF PHARMACOTHERAPY, 2003, 37 (7-8) : 1148 - 1148
  • [10] Tenofovir disoproxil fumarate
    Gallant, JE
    Deresinski, S
    CLINICAL INFECTIOUS DISEASES, 2003, 37 (07) : 944 - 950